CA 125 regression after two completed cycles of chemotherapy: Lack of prediction for long-term survival in patients with advanced ovarian cancer

British Journal of Cancer

Volumn 81, Issue 4, 1999, Pages 662-666

  Peters Engl, C ^a   Obermair, A ^b   Heinzl, H ^c   Buxbaum, P ^a   Sevelda, P ^a   Medl, M ^a  

^a GENERAL HOSPITAL LINZ   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

CA 125; Ovarian cancer; Prognosis

Indexed keywords

CA 125 ANTIGEN;

ADULT; ADVANCED CANCER; AGE; ARTICLE; CANCER SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NONBIOLOGICAL MODEL; OVARY CANCER; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0032886869     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690744     Document Type: Article

References (26)

1. Atack DB, Nisker JA, Allen HH, Tustanoff ER and Levin L (1986) CA 125 surveillance and second-look laparotomy in ovarian carcinoma. Am J Obstet Gynecol 154: 287-289
2. Averette HE, Janicek MF and Menek HR (1996) The National Cancer Data Base report on ovarian cancer. American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 76: 1096-1103
3. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Laevitt T, Griffiths CT, Parker L, Zurawski VR Jr and Knapp RC (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309: 883-887
4. Canney PA, Moore M, Wilkinson PM and James RD (1984) Ovarian cancer antigen CA 125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer 50: 765-769
5. Cox DR (1972) Regression models and life tables (with discussion). J Royal Statist Soc B 34: 187-220
6. Day TG, Gallagher HS and Rudledge FN (1975) Epithelial carcinoma of the ovary: prognostic importance of histologic grade. J Natl Cancer Inst 42: 15-21
7. Fayers PM, Rustin G, Wood R, Nelstrop A, Leonard RCF, Wilkinson P, Cruickshank D, McAllister EJ, Redman CWE, Parker D, Scott IV, Slevin ML and Roulston JE (1993) The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer. Int J Gynecol Cancer 3: 285-292
8. Hawkins RE, Roberts K, Wiltshaw E, Mundy J, Fryatt IJ and McCready VR (1989) The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol 96: 1395-1399
9. Heinzl H and Kaider A (1997) Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. Comp Meth Prog Biomed 54: 201-208
10. Hess KR (1994) Assessing time-by-covariate interactions in proportional hazards regression models using cubic spline functions. Statist Med 13: 1045-1062
11. Hunter VJ, Daly L, Helms M, Super JT, Berchuck A, Clarke-Pearson DL and Bast RC (1990) The prognostic significance of CA 125 half-life in patients with ovarian cancer who received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol 163: 1164-1167
12. International Federation of Gynaecology and Obstetrics (1987) Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 156: 263-264
13. Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Statist Assoc 53: 457-481
14. Krag KJ, Canellos GP, Griffiths CT, Knapp RC, Parker LM, Welch WR, Klatt M and Andersen J (1989) Predictive factors for long term survival in patients with advanced ovarian cancer. Gynecol Oncol 34: 88-93
15. Lavin PT, Knapp RC, Malkasian G, Whitney CW and Berek JC (1987) CA-125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol 69: 223-227
16. Makar AP, Kristensen GD, Bormer OP and Claes GT (1993) Serum CA 125 level allows early identification of non-responders during induction chemotherapy. Gynecol Oncol 49: 73-79
17. Mogenson O, Mogenson B and Jakobsen A (1990) Predictive value of CA 125 during early chemotherapy of advanced ovarian cancer. Gynecol Oncol 37: 44-46
18. Mogensen O (1992) Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol 44: 207-212
19. Redman CWE, Blackledge Jr, Kelly K, Powell J, Buxton EJ and Luesly DM (1990) Early serum CA 125 response and outcome in epithelial ovarian cancer. Eur J Cancer 26: 593-596
20. Rustin GJS, Gennings JN, Nelstrop AE, Covarrubias H, Lambert HE and Bagshawe KD (1989) Use of CA-125 to predict survival of patients with ovarian carcinoma. J Clin Oncol 11: 1667-1671
21. Serov SF, Scully RE and Sorbin LH (1973) Histological typing of ovarian tumors. IN: International Histological Classification of Tumors, pp. 17-18. World Health Organization: Geneva, Switzerland
22. Sevelda P, Sehemper M and Spona J (1989) CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. Am J Obstet Gynecol 161: 1213-1216
23. Swenerton KD, Hislop TG, Spinelli J, LeRiche JC, Yang N and Boyes DA (1985) Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol 65: 264-269
24. Van der Burgh MEL, Lammes FB, Van Putten WJL and Stotter G (1988) Ovarian cancer: the prognostic value of the serum half-life of CA-125 during the induction of chemotherapy. Gynecol Oncol 30: 307-312
25. Yedema CA, Kenemans P, Voorhorst F, Bon G, Schijf C, Beex L, Verstracten A, Hilgers J and Vermorken J (1993a) CA 125 half-life in ovarian cancer: a multivariate survival analysis. Br J Cancer 67: 1361-1367
26. Yedema CA, Kenemans P, Thomas CMG, Massager LFAG, Wobbes TH, Verstracten AA, van Kamp GJ, Hilgers J (1993b) CA 125 serum levels in the early postoperative period do not reflect the outcome of cytoreductive surgery. Eur J Cancer 29: 966-971